Premium
Teva Pharmaceutical Industries Ltd (TEVA)
NYSE
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Mr. Matthew ShieldsExec. VP of Global Operations | -9,99k | 321,55k | Vente | 32,19 | 0,00 | -100,00% |
| 2026-06-11 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -106,56k | 3,63M | Automatic Disposition | 34,10 | 65,62k | -61,89% |
| 2026-06-05 | Dr. Chen LichtensteinIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 19,30k | 301,67% |
| 2026-06-05 | Dr. Sol J. BarerIndependent Chairman of the Board | 21,74k | 0,00 | Derivative Exercise and Retained Stock | - | 448,01k | 5,10% |
| 2026-06-05 | Ms. Rosemary A. CraneIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 127,74k | 12,80% |
| 2026-06-05 | Mr. Gerald M. LiebermanIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 130,15k | 12,53% |
| 2026-06-05 | Mr. Perry D. NisenIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 119,81k | 13,76% |
| 2026-06-05 | Mr. Amir ElsteinIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 2,12M | 0,69% |
| 2026-06-05 | Mr. Roberto Agostino MignoneIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 119,81k | 13,76% |
| 2026-06-05 | Prof. Ronit Satchi-FainaroIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 112,40k | 14,80% |
| 2026-06-05 | Dr. Tal ZaksIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 73,26k | 24,66% |
| 2026-06-05 | Mr. Richard D. FrancisPresident, CEO & Director | 6,89k | 0,00 | Derivative Exercise and Retained Stock | - | 1,18M | 0,59% |
| 2026-06-05 | Mr. Richard D. FrancisPresident, CEO & Director | -6,15k | 211,36k | Derivative Exercise and Sale | 34,35 | 1,18M | - |
| 2026-06-03 | Mr. Matthew ShieldsExec. VP of Global Operations | -16,20k | 532,33k | Derivative Exercise and Sale | 32,87 | 9,99k | - |
| 2026-05-14 | Mr. Evan LippmanExec. VP of Business Development | 44,19k | 0,00 | Derivative Exercise and Retained Stock | - | 44,19k | - |
| 2026-05-14 | Mr. Evan LippmanExec. VP of Business Development | -41,66k | 1,48M | Derivative Exercise and Sale | 35,58 | 44,19k | - |
| 2026-05-14 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -153,25k | 5,46M | Automatic Disposition | 35,61 | 172,18k | -47,09% |
| 2026-05-06 | Mr. Amir WeissSenior VP & CAO | -10,68k | 384,44k | Vente | 36,00 | 20,02k | -34,79% |
| 2026-05-05 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -30,00k | 1,06M | Vente | 35,40 | 55,76k | -34,98% |
| 2026-05-01 | Mr. Mark SabagExec. VP of International Markets Commercial | -144,18k | 5,05M | Vente | 34,99 | 80,76k | -64,10% |
| 2026-04-30 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -21,26k | 750,62k | Vente | 35,31 | 63,65k | -25,04% |
| 2026-03-17 | Mr. Mark SabagExec. VP of International Markets Commercial | -62,10k | 1,87M | Vente | 30,14 | 224,94k | -21,64% |
| 2026-03-05 | Mr. Mark SabagExec. VP of International Markets Commercial | 15,72k | 0,00 | Derivative Exercise and Retained Stock | - | 287,04k | 5,80% |
| 2026-03-05 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 19,92k | 0,00 | Derivative Exercise and Retained Stock | - | 325,44k | 6,52% |
| 2026-03-05 | Mr. Amir WeissSenior VP & CAO | 3,54k | 0,00 | Derivative Exercise and Retained Stock | - | 30,70k | 13,02% |
| 2026-03-05 | Mr. Richard D. FrancisPresident, CEO & Director | 22,43k | 0,00 | Derivative Exercise and Retained Stock | - | 1,17M | 1,95% |
| 2026-03-05 | Mr. Richard D. FrancisPresident, CEO & Director | -20,03k | 634,16k | Derivative Exercise and Sale | 31,67 | 1,17M | - |
| 2026-03-05 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 9,90k | 0,00 | Derivative Exercise and Retained Stock | - | 84,91k | 13,19% |
| 2026-03-05 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -7,92k | 250,94k | Derivative Exercise and Sale | 31,67 | 84,91k | - |
| 2026-03-05 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 10,12k | 0,00 | Derivative Exercise and Retained Stock | - | 107,71k | 10,37% |
| 2026-03-05 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -9,53k | 301,89k | Derivative Exercise and Sale | 31,67 | 107,71k | - |
| 2026-03-05 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -17,30k | 547,70k | Derivative Exercise and Sale | 31,67 | 85,76k | - |
| 2026-03-05 | Mr. Placid JoverExec. VP & CHRO | -14,15k | 448,11k | Derivative Exercise and Sale | 31,67 | 6,77k | - |
| 2026-03-05 | Mr. Brian SavageInterim Chief Legal Officer | 2,45k | 0,00 | Derivative Exercise and Retained Stock | - | 10,91k | 28,99% |
| 2026-03-05 | Mr. Brian SavageInterim Chief Legal Officer | -1,13k | 35,69k | Derivative Exercise and Sale | 31,67 | 10,91k | - |
| 2026-03-05 | Mr. Matthew ShieldsExec. VP of Global Operations | -17,30k | 547,70k | Derivative Exercise and Sale | 31,67 | 9,99k | - |
| 2026-03-04 | Mr. Richard D. FrancisPresident, CEO & Director | 26,83k | 0,00 | Derivative Exercise and Retained Stock | - | 1,15M | 2,39% |
| 2026-03-04 | Mr. Richard D. FrancisPresident, CEO & Director | -23,39k | 759,44k | Derivative Exercise and Sale | 32,46 | 1,15M | - |
| 2026-03-04 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -53,97k | 1,75M | Derivative Exercise and Sale | 32,46 | 85,76k | - |
| 2026-03-04 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -37,37k | 1,23M | Automatic Disposition | 32,95 | 85,76k | -30,35% |
| 2026-03-04 | Mr. Mark SabagExec. VP of International Markets Commercial | 52,11k | 0,00 | Derivative Exercise and Retained Stock | - | 271,32k | 23,77% |
| 2026-03-04 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 11,97k | 0,00 | Derivative Exercise and Retained Stock | - | 97,59k | 13,99% |
| 2026-03-04 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -11,28k | 366,10k | Derivative Exercise and Sale | 32,46 | 97,59k | - |
| 2026-03-04 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 56,76k | 0,00 | Derivative Exercise and Retained Stock | - | 305,52k | 22,82% |
| 2026-03-04 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 11,36k | 0,00 | Derivative Exercise and Retained Stock | - | 75,01k | 17,85% |
| 2026-03-04 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -9,10k | 295,36k | Derivative Exercise and Sale | 32,46 | 75,01k | - |
| 2026-03-04 | Mr. Brian SavageInterim Chief Legal Officer | 5,54k | 0,00 | Derivative Exercise and Retained Stock | - | 8,46k | 189,17% |
| 2026-03-04 | Mr. Brian SavageInterim Chief Legal Officer | -2,68k | 86,84k | Derivative Exercise and Sale | 32,46 | 8,46k | - |
| 2026-03-04 | Mr. Amir WeissSenior VP & CAO | 16,33k | 0,00 | Derivative Exercise and Retained Stock | - | 27,16k | 150,79% |
| 2026-03-03 | Mr. Amir WeissSenior VP & CAO | 5,18k | 0,00 | Derivative Exercise and Retained Stock | - | 10,83k | 91,66% |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | 141,48k | 0,00 | Derivative Exercise and Retained Stock | - | 123,13k | -770,96% |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -62,25k | 2,01M | Derivative Exercise and Sale | 32,36 | 123,13k | - |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -66,74k | 2,16M | Automatic Disposition | 32,36 | 123,13k | -35,15% |
| 2026-03-03 | Mr. Mark SabagExec. VP of International Markets Commercial | 166,38k | 0,00 | Derivative Exercise and Retained Stock | - | 219,21k | 314,94% |
| 2026-03-03 | Mr. Brian SavageInterim Chief Legal Officer | 2,19k | 0,00 | Derivative Exercise and Retained Stock | - | 2,93k | 295,94% |
| 2026-03-03 | Mr. Brian SavageInterim Chief Legal Officer | -1,27k | 41,23k | Derivative Exercise and Sale | 32,36 | 2,93k | - |
| 2026-03-03 | Mr. Richard D. FrancisPresident, CEO & Director | 515,61k | 0,00 | Derivative Exercise and Retained Stock | - | 1,12M | 85,12% |
| 2026-03-03 | Mr. Richard D. FrancisPresident, CEO & Director | -442,94k | 14,33M | Derivative Exercise and Sale | 32,36 | 1,12M | - |
| 2026-03-03 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 191,28k | 0,00 | Derivative Exercise and Retained Stock | - | 248,76k | 332,78% |
| 2026-03-03 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 85,62k | 0,00 | Derivative Exercise and Retained Stock | - | 85,62k | - |
| 2026-03-03 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -80,76k | 2,61M | Derivative Exercise and Sale | 32,36 | 85,62k | - |
| 2026-02-26 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -345,81k | 11,63M | Automatic Disposition | 33,64 | 57,48k | -85,75% |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | 620,11k | 0,00 | Derivative Exercise and Retained Stock | - | 605,77k | -4 324,64% |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | -161,66k | 5,53M | Derivative Exercise and Sale | 34,22 | 605,77k | - |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | -286,12k | 9,79M | Automatic Disposition | 34,22 | 605,77k | -32,08% |
| 2025-12-16 | Mr. Amir WeissSenior VP & CAO | -12,30k | 371,50k | Vente | 30,20 | 5,65k | -68,52% |
| 2025-12-16 | Bridger Management LLCSociété | -77,40k | 2,34M | Vente | 30,24 | 367,60k | -17,39% |
| 2025-12-09 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -115,47k | 1,19M | Derivative Exercise and Sale | 16,99 - 28,68 | 48,38k | - |
| 2025-12-09 | Mr. Mark SabagExec. VP of International Markets Commercial | -118,72k | 1,20M | Derivative Exercise and Sale | 18,61 - 28,75 | 52,83k | - |
| 2025-12-09 | Mr. Mark SabagExec. VP of International Markets Commercial | -98,17k | 2,82M | Vente | 28,70 | 52,83k | -65,01% |
| 2025-12-02 | Dr. Chen LichtensteinIndependent Director | 4,80k | 0,00 | Derivative Exercise and Retained Stock | - | 4,80k | - |
| 2025-11-26 | Bridger Management LLCSociété | -50,00k | 1,30M | Vente | 26,03 | 445,00k | -10,10% |
| 2025-11-20 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 35,26k | 0,00 | Derivative Exercise and Retained Stock | - | 63,65k | 124,24% |
| 2025-11-20 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -28,23k | 699,52k | Derivative Exercise and Sale | 24,78 | 63,65k | - |
| 2025-11-14 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -30,00k | 753,32k | Vente | 25,11 | 28,38k | -51,38% |
| 2025-11-06 | Bridger Management LLCSociété | -200,00k | 4,82M | Vente | 24,11 | 495,00k | -28,78% |
| 2025-11-06 | Mr. Amir WeissSenior VP & CAO | -12,30k | 300,56k | Vente | 24,44 | 17,95k | -40,66% |
| 2025-09-05 | Mr. David R. McavoyInitié | 1,11k | 20,99k | Achat | 18,86 | 13,03k | 9,34% |
| 2025-08-01 | Mr. Placid JoverExec. VP & CHRO | 6,77k | 0,00 | Derivative Exercise and Retained Stock | - | 6,77k | - |
| 2025-08-01 | Mr. Placid JoverExec. VP & CHRO | -6,05k | 91,75k | Derivative Exercise and Sale | 15,16 | 6,77k | - |
| 2025-08-01 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -52,74k | 799,44k | Derivative Exercise and Sale | 15,16 | 0,00 | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
